Results 221 to 230 of about 38,540 (306)

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma. [PDF]

Blood Cancer J
Jurgens E, Shekarkhand T, Rueda C, Nemirovsky D, Derkach A, Firestone RS, Miller K, Costa BA, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Hamadeh I, Giralt SA, Shah GL, Landau HJ, Scordo M, Usmani SZ, Mailankody S, Shahid Z.   +24 more
europepmc   +1 more source

In vivo CAR therapies: Turning the patient into their own CAR factory

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)‐T‐cell therapies have reshaped the treatment of B‐cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufacturing processes, demanding logistics, long turnaround times, and substantial costs. In vivo CAR approaches
François Vilcot, Carole‐Anne Brugère, Jaime Fuentealba, Roch Houot   +3 more
wiley   +1 more source

Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US. [PDF]

Future Oncol
Graff T, Bains Chawla S, Jun M, Heaps N, Alshreef A, Tybor D, Moore DC, Zawadzki N, Spurrier K, Shafrin J.   +9 more
europepmc   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

Bispecific Antibodies in Solid Tumors: Advances and Challenges. [PDF]

Int J Mol Sci
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, Dalal M, Ferraro P, Hussein A, Vulfovich M.   +7 more
europepmc   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma. [PDF]

Blood Adv
Rios-Olais FA, Hilal T.
europepmc   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy

MedComm, Volume 7, Issue 5, May 2026.
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
Wanlin He, Andrew J. McMichael
wiley   +1 more source

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. [PDF]

Front Oncol
Garfall AL, Banerjee R, Frenzel L, Khandanpour C, Lin Y, Ottoni E, Rifkin R, Rockwell S, Rodriguez C, Villefort H, Zamagni E.   +10 more
europepmc   +1 more source